Posterior cerebral artery

Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System

Retrieved on: 
Monday, April 24, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, Health, Medical Devices, Inflammation, Infection, Tissue, TASS, Allergy, IOP, Cornea, Sodium, Surgeon, Use, Cataract, Eye, Clinical trial, Particulates, OVD, Decompensation, Sale, Direction, Aqueous humour, Intraocular pressure, Bausch & Lomb, Hurtigruten AS, Patient, Phacoemulsification, Freezing, Risk, Cannula, Radical (chemistry), Sorbitol, Paratriathlon, Regulation of tobacco by the U.S. Food and Drug Administration, IOL, NYSE, Posterior cerebral artery, Food, Veterinary medicine, Dentistry, Medical device, Birth control, Pharmaceutical industry, Dry cleaning

Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of StableVisc™ cohesive ophthalmic viscosurgical device (OVD) as well as TotalVisc™ Viscoelastic System.
  • TotalVisc Viscoelastic System includes both StableVisc and ClearVisc™, a dispersive OVD, and protects ocular tissue during the surgical procedure.
  • TotalVisc is the only dual pack in the United States that includes a dispersive and cohesive OVD formulated with sorbitol.
  • Federal (USA) law restricts this device to the sale by or on the order of a physician.

Aidoc Secures New FDA Clearances Enabling Faster and More Accurate Detection of Critical Neurological and Cardiovascular Conditions

Retrieved on: 
Thursday, November 17, 2022
Triage, AD, LVO, Thoracic aortic aneurysm, EHR, Surgery, Stroke, Length of stay, Mevo, Radiology, Physician, M1, FDA, Doctor Foster, Aidoc, ICA, Computer-aided simple triage, Intelligence, Abdominal aortic aneurysm, Middle cerebral artery, Anterior cerebral artery, Patient, PCA, COVID-19, Pressure, Surgeon, Communication, Basilar artery, Posterior cerebral artery, Brain, Vos, MCA, AI, Vertebral artery, ACA, Ambient occlusion, Yale New Haven Hospital, CT, Medical device, Medicine, Medical imaging, Mevo Modi'im

NEW YORK, Nov. 17, 2022 /PRNewswire/ -- Aidoc, the leading provider of healthcare AI solutions, today announced it has increased its FDA clearances to 11 with the addition of CT-based AI solutions - aortic dissection (AD) and all vessel occlusions (VOs). These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.

Key Points: 
  • These clearances continue Aidoc's impressive momentum and leadership in healthcare AI, giving the organization the most FDA clearances in the AI imaging space.
  • "Effective healthcare and treatment of acute conditions, like stroke and aortic dissections, require rapid, coordinated care minutes can matter," said Aidoc CEO Elad Walach.
  • Aidoc is the only company with a proven EHR integration for the population of critical, time-sensitive patient information on the app.
  • Aidoc is the leading provider of artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance quality of care.